Detalhe da pesquisa
1.
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.
Cancer Cell
; 12(4): 367-80, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17936561
2.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Cancer Cell
; 7(4): 387-97, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15837627
3.
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Oncogene
; 24(56): 8259-67, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16091734
4.
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Blood
; 106(2): 721-4, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15790786
5.
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.
Blood
; 106(2): 494-504, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15784726
6.
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Blood
; 106(9): 3206-13, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16030188
7.
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Proc Natl Acad Sci U S A
; 101(40): 14479-84, 2004 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-15448205